Our group and others have previously developed some preclinical targeted-based approaches for PET imaging of MT1-MMP overexpression in glioma, pancreatic cancer, and bone sarcoma (17, 18, 29) based on the full-length IgG murine anti-MT1-MMP monoclonal antibody LEM2/15 (30) or by using radiofluorinated MT1-MMP substrate peptides conjugated to BODIPY650/665 and polyethylene glycol (PEG) for a dual PET/optimal imaging (31). Here, LEMD2 is linked to pancreatic neoplasm.